Projects

Daniel Muema’s work will contribute to informing how HIV vaccines can be designed to confer long-lasting protection from HIV infection. So far, a licensed effective HIV vaccine does not exist. There are, however, several candidate HIV vaccines in early stages…

The development of an effective HIV vaccine has been hindered mainly due to the ability of the virus to evolve and escape the host’s defence system. However, the discovery and analysis of highly networked epitopes (regions/parts) of the virus has…

Despite more than three decades of research, a protective vaccine against HIV-1 group M (HIV-1M) remains elusive. To date, none of the vaccine candidates tested has been able to induce effective humoral immunity. Nevertheless, neutralising antibodies (nAbs) in the broad…

Aurélie Kifack Zetang’s project focusses on the molecular epidemiology of non-M HIV-1 variants and dual M+O HIV-1 infections in HIV-positive patients in Cameroon. HIV-1 is very diverse and this high genetic diversity has an impact on the diagnosis, treatment and…

Despite the success of antiretroviral therapy (ART) in managing clinical disease and preventing viral transmission, there is still no vaccine or cure for HIV. The persistence of virus-infected human cells that remain dormant during ART, poses a significant barrier to…

Maseema and his team aim to uncover immune correlates of protection in subclinical Mycobacterial tuberculosis (Mtb) infection and TB disease. The majority of individuals who are exposed to Mtb infection successfully contain the infection whereby only an immunological memory remains…

The main objective of Katoba’s study is to explore barriers and challenges related to the accessibility of point-of-care (POC) diagnostics for prevention of vertically transmitted infections in rural primary health care clinic (PHCs) settings of Zambia. The specific aims are:…

Uganda still falls short of the World Health Organisation’s targets of viral load suppression among the breastfeeding and pregnant women. This may be explained by increased levels of HIV-1 drug resistance mutations (HIV-DRMs) subsequently increasing the risk of vertical transmission…